Holen Sie sich die Stockscreener-App
25.93
2.90%
0.73
Handel nachbörslich:
25.90
-0.03
-0.12%
Schlusskurs vom Vortag:
$25.20
Offen:
$25.2
24-Stunden-Volumen:
479.84K
Relative Volume:
1.19
Marktkapitalisierung:
$1.14B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.22%
1M Leistung:
+78.95%
6M Leistung:
+135.51%
1J Leistung:
+0.00%
1-Tages-Spanne:
$24.42
$26.45
1-Wochen-Bereich:
$24.42
$28.37
52-Wochen-Spanne:
$6.71
$28.37
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
25.93 | 1.11B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Detecting price anomalies in Maze Therapeutics Inc. with AIJuly 2025 Rallies & Community Supported Trade Ideas - newser.com
Predicting Maze Therapeutics Inc. trend using moving averagesJuly 2025 Sector Moves & Short-Term High Return Ideas - newser.com
Goldman Sachs Group Inc. Makes New $145,000 Investment in Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 5.2%Should You Sell? - MarketBeat
What technical models suggest about Maze Therapeutics Inc.’s comebackDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Developing predictive dashboards with Maze Therapeutics Inc. dataJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
What drives Maze Therapeutics Inc stock priceAnalyst Downgrades & High Yield Trading Growth - earlytimes.in
What analysts say about Maze Therapeutics Inc stockEarnings Beat Highlights & Outstanding Trading Tips - earlytimes.in
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.4%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week HighHere's Why - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives $32.67 Average PT from Analysts - Defense World
How hedge fund analytics apply to Maze Therapeutics Inc. stock2025 Institutional Moves & Weekly Top Performers Watchlists - newser.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
HC Wainwright Reaffirms Buy Rating for Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Analyzing Maze Therapeutics (NASDAQ:MAZE) and Syndax Pharmaceuticals (NASDAQ:SNDX) - Defense World
Institution Moves: What’s the fair value of Maze Therapeutics Inc. stock2025 Price Momentum & Stepwise Entry/Exit Trade Alerts - خودرو بانک
Candlestick signals on Maze Therapeutics Inc. stock todayTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Maze Therapeutics (NASDAQ:MAZE) Director Sells $464,043.28 in Stock - MarketBeat
Maze Therapeutics Inc. stock trend outlook and recovery pathNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
Market reaction to Maze Therapeutics Inc.’s recent newsIPO Watch & Community Driven Trade Alerts - newser.com
Will Maze Therapeutics Inc. rebound enough to break even2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Maze Therapeutics, Inc. (MAZE): A Bull Case Theory - Insider Monkey
Maze Therapeutics (NASDAQ:MAZE) Receives “Buy” Rating from HC Wainwright - Defense World
Can Maze Therapeutics Inc. recover in the next quarterQuarterly Profit Summary & Weekly Top Performers Watchlists - newser.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - Investing.com
Tools to monitor Maze Therapeutics Inc. recovery probability2025 Support & Resistance & Safe Entry Zone Tips - newser.com
Analyzing drawdowns of Maze Therapeutics Inc. with statistical toolsJuly 2025 Summary & Proven Capital Preservation Methods - newser.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - sharewise.com
Maze Therapeutics (NASDAQ:MAZE) Shares Gap DownHere's Why - MarketBeat
Maze Therapeutics director Scheller sells $464k in shares By Investing.com - Investing.com Australia
New Options Available for Maze Therapeutics (MAZE) - GuruFocus
Quarterly Recap: Will COOT outperform tech stocks2025 Valuation Update & Consistent Growth Stock Picks - خودرو بانک
Maze Therapeutics Director Cashes Out in Major Stock Sale! - TipRanks
Maze Therapeutics Inc. stock daily chart insightsQuarterly Portfolio Summary & Community Verified Watchlist Alerts - newser.com
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):